{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:44:13Z","timestamp":1790113453764,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109412","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:33:10Z","timestamp":1777501990000},"page":"109412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients"],"prefix":"10.1016","volume":"217","author":[{"given":"Haibo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijin","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haipeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiquan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhangzhou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109412_b0005","doi-asserted-by":"crossref","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 2024;4:47-53. https:\/\/doi: 10.1016\/j.jncc.2024.01.006.","DOI":"10.1016\/j.jncc.2024.01.006"},{"key":"10.1016\/j.lungcan.2026.109412_b0010","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2026.109412_b0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143515","article-title":"Molecular epidemiology of EGFR mutations in asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - mainland China subset analysis of the PIONEER study","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.lungcan.2026.109412_b0020","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2026.109412_b0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109412_b0030","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109412_b0035","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-19-1446","article-title":"Targeting MET dysregulation in cancer","volume":"10","author":"Recondo","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.109412_b0040","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): a multicentre, open-label, phase 1b\/2 study","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2026.109412_b0045","first-page":"1159","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: final results from a multicentre, open-label, phase 1b study","volume":"8","author":"Sequist","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.lungcan.2026.109412_b0050","first-page":"S1572","article-title":"Tepotinib + osimertinib for EGFRm NSCLC with MET amplification after failure on first-line osimertinib: INSIGHT 2 study","volume":"33","author":"Ahn","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109412_b0055","first-page":"9121","article-title":"Phase II study of SCC244 (glumetinib mesylate) in combination with osimertinib in patients with EGFR-mutant, MET-dysregulated advanced non-small cell lung cancer (SCC244-203)","volume":"40","author":"Lu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109412_b0060","unstructured":"Lu S, et al. Phase Ib\/II study of vebreltinib plus andaitinib in patients with advanced NSCLC harboring EGFR mutation and MET amplification\/overexpression after progression on EGFR-TKIs. In: Proceedings of the ESMO Asia Congress; 2025; Singapore."},{"key":"10.1016\/j.lungcan.2026.109412_b0065","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 3.2025. Plymouth Meeting, PA: National Comprehensive Cancer Network; 2025."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109412_b0070","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109412_b0075","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1158\/2159-8290.CD-18-1022","article-title":"Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and MET inhibition with osimertinib and savolitinib","volume":"8","author":"Piotrowska","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2026.109412_b0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109412_b0085","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamaoncol.2018.2969","article-title":"Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-positive lung cancer and acquired resistance to osimertinib","volume":"4","author":"Oxnard","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2026.109412_b0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12920-021-00909-y","article-title":"Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation","volume":"14","author":"Heydt","year":"2021","journal-title":"BMC Med. Genomics"},{"key":"10.1016\/j.lungcan.2026.109412_b0095","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109412_b0100","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s40265-021-01584-0","article-title":"Savolitinib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.lungcan.2026.109412_b0105","unstructured":"Ahn MJ, Tsai CM, Yang JC, et al. 308O AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer and brain metastases: data from Phase II studies. Ann Oncol 2015;26:ix94-ix103.https:\/\/doi.org\/10.1093\/annonc\/mdv332.08."},{"key":"10.1016\/j.lungcan.2026.109412_b0110","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109412_b0115","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","article-title":"Tracking the evolution of non-small-cell lung cancer","volume":"376","author":"Jamal-Hanjani","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109412_b0120","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41416-021-01558-9","article-title":"Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer","volume":"125","author":"Martinez-Marti","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109412_b0125","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2026.109412_b0130","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.21037\/tlcr-24-273","article-title":"Detailed characterization of combination treatment with MET inhibitor plus EGFR inhibitor in EGFR-mutant and MET-amplified non-small cell lung cancer","volume":"13","author":"Lee","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109412_b0135","article-title":"Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study","volume":"199","author":"van der Wel","year":"2025","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004733?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004733?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:04:37Z","timestamp":1783141477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":27,"alternative-id":["S0169500226004733"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109412","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vebreltinib plus EGFR-TKI for EGFR-mutated NSCLC with MET-driven resistance: A real-world study of Chinese patients","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109412"}}